It has been a challenge for decades in the central nervous system (CNS) to discover a new target for pain relief that is both safe and can also compete with, or even replace, opioid options.
In December 2024, XGene Pharmaceutical, a Shanghai-based startup, released positive top-line results from a US Phase IIb/III trial with XG005, its non-opioid, dual-targeting analgesic,
Key Takeaways
- XGene’s XG005, a non-opioid, dual-targeting analgesic that conjugates naproxen and pregabalin, has shown promise in addressing safety and pharmacokinetics issues of the two drugs alone in moderate-to-severe pain.
- A US Phase IIb/III trial for acute pain in bunionectomy, its initial indication, met both its primary and key secondary endpoints with a favorable safety profile
